RU2015120216A - Ингибиторы тирозинкиназы брутона - Google Patents
Ингибиторы тирозинкиназы брутона Download PDFInfo
- Publication number
- RU2015120216A RU2015120216A RU2015120216A RU2015120216A RU2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A RU 2015120216 A RU2015120216 A RU 2015120216A
- Authority
- RU
- Russia
- Prior art keywords
- fluoro
- oxo
- tert
- butyl
- phthalazin
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 230000001363 autoimmune Effects 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- -1 methyl pyrazolyl Chemical group 0.000 claims 2
- RHQADMUNQPFMKD-UHFFFAOYSA-N 6-tert-butyl-2-[[2,6-difluoro-4-(2-oxo-1h-pyridin-4-yl)phenyl]methyl]-8-fluorophthalazin-1-one Chemical compound C=1C(C(C)(C)C)=CC(F)=C(C2=O)C=1C=NN2CC(C(=C1)F)=C(F)C=C1C=1C=CNC(=O)C=1 RHQADMUNQPFMKD-UHFFFAOYSA-N 0.000 claims 1
- XPWHPDCOARLMAB-UHFFFAOYSA-N 6-tert-butyl-8-fluoro-2-[2-(hydroxymethyl)-3-(2-oxo-1h-pyridin-4-yl)phenyl]phthalazin-1-one Chemical compound C=1C(C(C)(C)C)=CC(F)=C(C2=O)C=1C=NN2C(C=1CO)=CC=CC=1C=1C=CNC(=O)C=1 XPWHPDCOARLMAB-UHFFFAOYSA-N 0.000 claims 1
- IMQBHYSXBWWOOO-UHFFFAOYSA-N 6-tert-butyl-8-fluoro-2-[[2-(hydroxymethyl)-4-(2-oxo-1h-pyridin-4-yl)phenyl]methyl]phthalazin-1-one Chemical compound C=1C(C(C)(C)C)=CC(F)=C(C2=O)C=1C=NN2CC(C(=C1)CO)=CC=C1C=1C=CNC(=O)C=1 IMQBHYSXBWWOOO-UHFFFAOYSA-N 0.000 claims 1
- MZHGUVIVLIVZQD-UHFFFAOYSA-N 6-tert-butyl-8-fluoro-2-[[2-fluoro-4-(2-oxo-1h-pyridin-4-yl)phenyl]methyl]phthalazin-1-one Chemical compound C=1C(C(C)(C)C)=CC(F)=C(C2=O)C=1C=NN2CC(C(=C1)F)=CC=C1C=1C=CNC(=O)C=1 MZHGUVIVLIVZQD-UHFFFAOYSA-N 0.000 claims 1
- BNKQWYPBCRMGFD-UHFFFAOYSA-N 6-tert-butyl-8-fluoro-2-[[2-fluoro-4-[2-(1-methylpyrazol-4-yl)-6-oxo-1h-pyridin-4-yl]phenyl]methyl]phthalazin-1-one Chemical compound C1=NN(C)C=C1C1=CC(C=2C=C(F)C(CN3C(C4=C(F)C=C(C=C4C=N3)C(C)(C)C)=O)=CC=2)=CC(=O)N1 BNKQWYPBCRMGFD-UHFFFAOYSA-N 0.000 claims 1
- RIMMMRIRYIRMQX-UHFFFAOYSA-N 6-tert-butyl-8-fluoro-2-[[3-(hydroxymethyl)-4-(2-oxo-1h-pyridin-4-yl)phenyl]methyl]phthalazin-1-one Chemical compound C=1C(C(C)(C)C)=CC(F)=C(C2=O)C=1C=NN2CC(C=C1CO)=CC=C1C=1C=CNC(=O)C=1 RIMMMRIRYIRMQX-UHFFFAOYSA-N 0.000 claims 1
- HAKHTBNVQLRBOE-UHFFFAOYSA-N 6-tert-butyl-8-fluoro-2-[[4-(2-oxo-1h-pyridin-4-yl)phenyl]methyl]phthalazin-1-one Chemical compound C=1C(C(C)(C)C)=CC(F)=C(C2=O)C=1C=NN2CC(C=C1)=CC=C1C=1C=CNC(=O)C=1 HAKHTBNVQLRBOE-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/82—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (29)
1. Соединение Формулы I,
где:
А представляет собой фталазин, возможно замещенный одним или более А';
А' представляет собой трет-бутил, F или оксо;
каждый R1 независимо представляет собой F или гидроксиметил;
m равно 1;
R2 представляет собой метил пиразолил;
n представляет собой 0; и
X представляет собой СН2;
или его фармацевтически приемлемая соль.
2. Соединение по п. 1, выбранное из группы, состоящей из:
6-трет-бутил-8-фтор-2-[4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2Н-фталазин-1-он;
6-трет-бутил-8-фтор-2-[2-фтор-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2Н-фталазин-1-он;
6-трет-бутил-8-фтор-2-[2-гидроксиметил-3-(2-оксо-1,2-дигидро-пиридин-4-ил)-фенил]-2Н-фталазин-1-он;
6-трет-бутил-2-[2,6-дифтор-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-8-фтор-2Н-фталазин-1-он;
6-трет-бутил-8-фтор-2-[2-гидроксиметил-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2H-фталазин-1-он;
6-трет-бутил-8-фтор-2-{2-фтор-4-[6-(1-метил-1Н-пиразол-4-ил)-2-оксо-1,2-дигидро-пиридин-4-ил]-бензил}-2H-фталазин-1-он;
6-трет-бутил-8-фтор-2-[3-гидроксиметил-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2H-фталазин-1-он; и
6-трет-бутил-8-фтор-2-[2-фтор-5-гидроксиметил-4-(2-оксо-1,2-дигидро-пиридин-4-ил)-бензил]-2Н-фталазин-1-он.
3. Способ лечения воспалительного и/или аутоиммунного состояния содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения по любому из пп. 1 или 2.
4. Способ лечения воспалительного состояния, содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединения по любому из пп. 1 или 2.
5. Способ лечения ревматоидного артрита, содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединение по любому из пп. 1 или 2.
6. Способ лечения астмы, содержащий введение нуждающемуся в этом пациенту терапевтически эффективного количества соединение по любому из пп. 1 или 2.
7. Фармацевтическая композиция, содержащая соединение по любому из пп. 1 или 2, смешанное по меньшей мере с одним фармацевтически приемлемым носителем, эксципиентом или разбавителем.
8. Применение соединения по любому из пп. 1 или 2 в качестве терапевтически активного вещества.
9. Применение соединения по любому из пп. 1 или 2 для получения лекарственного средства для лечения воспалительного и/или аутоиммунного состояния.
10. Применение соединения по любому из пп. 1 или 2 для лечения воспалительного и/или аутоиммунного состояния.
11. Соединение по любому из пп. 1 или 2 для применения для лечения воспалительного и/или аутоиммунного состояния.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261727130P | 2012-11-16 | 2012-11-16 | |
| US61/727,130 | 2012-11-16 | ||
| PCT/EP2013/073667 WO2014076104A1 (en) | 2012-11-16 | 2013-11-13 | Inhibitors of bruton's tyrosine kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015120216A true RU2015120216A (ru) | 2017-01-10 |
Family
ID=49584724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015120216A RU2015120216A (ru) | 2012-11-16 | 2013-11-13 | Ингибиторы тирозинкиназы брутона |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9458105B2 (ru) |
| EP (1) | EP2920162B1 (ru) |
| JP (1) | JP6088063B2 (ru) |
| KR (1) | KR101713465B1 (ru) |
| CN (1) | CN104812746B (ru) |
| AR (1) | AR093478A1 (ru) |
| BR (1) | BR112015010693A2 (ru) |
| CA (1) | CA2890671A1 (ru) |
| MX (1) | MX2015006162A (ru) |
| RU (1) | RU2015120216A (ru) |
| TW (1) | TW201425297A (ru) |
| WO (1) | WO2014076104A1 (ru) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190330226A1 (en) * | 2018-04-26 | 2019-10-31 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
| CN109180642A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类btk抑制剂及其应用 |
| CN109172592A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种抗肿瘤药物组合物 |
| CN109288830A (zh) * | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型酞嗪酮类化合物联合用药物组合物 |
| CN109180643A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型a及其制备方法 |
| CN109336863A (zh) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型酞嗪酮类btk抑制剂、制备及其应用 |
| CN109369619A (zh) * | 2018-10-04 | 2019-02-22 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型b及其制备方法 |
| CN109336864A (zh) * | 2018-10-04 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 酞嗪酮类化合物晶型n及其制备方法 |
| CN109180644A (zh) * | 2018-10-04 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的甲磺酸盐及其制备方法与用途 |
| CN109485636A (zh) * | 2018-10-04 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的盐酸盐及其制备方法与用途 |
| CN109293635A (zh) * | 2018-10-04 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种新型btk激酶抑制剂的p晶型及其制备方法 |
| CN109394765A (zh) * | 2018-10-31 | 2019-03-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和对苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109481443A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和邻苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109481444A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和酞嗪类btk抑制剂联合用药物组合物及其应用 |
| CN109223759A (zh) * | 2018-10-31 | 2019-01-18 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109481442A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和邻苯基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109288841A (zh) * | 2018-10-31 | 2019-02-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和对苯氟酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109481441A (zh) * | 2018-10-31 | 2019-03-19 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109331005A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和氟酞嗪类btk抑制剂联合用药物组合物及其应用 |
| CN109276571A (zh) * | 2018-10-31 | 2019-01-29 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和新型硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
| CN109394766A (zh) * | 2018-10-31 | 2019-03-01 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和对苯硝基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| CN109331018A (zh) * | 2018-10-31 | 2019-02-15 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
| CN109172562A (zh) * | 2018-10-31 | 2019-01-11 | 南京先进生物材料与过程装备研究院有限公司 | 一种紫杉醇和甲氧基酞嗪酮类btk抑制剂联合用药物组合物及其应用 |
| EP4051679A1 (en) * | 2019-10-30 | 2022-09-07 | Biogen MA Inc. | Condensed pyridazine or pyrimidine as btk inhibitors |
| CN116917279A (zh) * | 2020-08-07 | 2023-10-20 | 渤健马萨诸塞州股份有限公司 | Btk抑制剂 |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1045750A (ja) * | 1995-09-20 | 1998-02-17 | Takeda Chem Ind Ltd | アゾール化合物、その製造方法及び用途 |
| GB0111078D0 (en) * | 2001-05-04 | 2001-06-27 | Novartis Ag | Organic compounds |
| RU2505538C2 (ru) * | 2008-02-05 | 2014-01-27 | Ф.Хоффманн-Ля Рош Аг | Новые пиридиноны и пиридазиноны |
| RU2500680C2 (ru) * | 2008-06-24 | 2013-12-10 | Ф.Хоффманн-Ля Рош Аг | Новые замещенные пиридин-2-оны и пиридазин-3-оны |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| KR101837223B1 (ko) * | 2010-09-01 | 2018-03-09 | 질레드 코네티컷 인코포레이티드 | 피리디논/피라지논, 그의 제조 방법 및 사용 방법 |
| EP2709997B1 (en) * | 2011-05-17 | 2016-06-29 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| BR112014003582A2 (pt) * | 2011-08-17 | 2017-03-14 | Hoffmann La Roche | inibidores da tirosina quinase de bruton |
| CA2853967A1 (en) * | 2011-11-03 | 2013-05-10 | F. Hoffmann-La Roche Ag | 8-fluorophthalazin-1 (2h) -one compounds as inhibitors of btk activity |
| EP2788347A1 (en) * | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| EP2895473A1 (en) * | 2012-09-13 | 2015-07-22 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| US9663494B2 (en) * | 2013-03-05 | 2017-05-30 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| KR101737724B1 (ko) * | 2013-03-05 | 2017-05-29 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| HK1214820A1 (zh) * | 2013-07-03 | 2016-08-05 | 豪夫迈．罗氏有限公司 | 雜芳基吡啶酮和氮雜-吡啶酮酰胺化合物 |
-
2013
- 2013-11-13 CA CA2890671A patent/CA2890671A1/en not_active Abandoned
- 2013-11-13 EP EP13791795.1A patent/EP2920162B1/en not_active Not-in-force
- 2013-11-13 WO PCT/EP2013/073667 patent/WO2014076104A1/en active Application Filing
- 2013-11-13 BR BR112015010693A patent/BR112015010693A2/pt not_active Application Discontinuation
- 2013-11-13 RU RU2015120216A patent/RU2015120216A/ru not_active Application Discontinuation
- 2013-11-13 CN CN201380059533.0A patent/CN104812746B/zh not_active Expired - Fee Related
- 2013-11-13 JP JP2015542251A patent/JP6088063B2/ja not_active Expired - Fee Related
- 2013-11-13 KR KR1020157015815A patent/KR101713465B1/ko not_active Expired - Fee Related
- 2013-11-13 US US14/441,711 patent/US9458105B2/en not_active Expired - Fee Related
- 2013-11-13 MX MX2015006162A patent/MX2015006162A/es unknown
- 2013-11-14 AR ARP130104183A patent/AR093478A1/es unknown
- 2013-11-15 TW TW102141777A patent/TW201425297A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR093478A1 (es) | 2015-06-10 |
| US20150291525A1 (en) | 2015-10-15 |
| EP2920162B1 (en) | 2017-04-19 |
| KR20150084061A (ko) | 2015-07-21 |
| WO2014076104A1 (en) | 2014-05-22 |
| TW201425297A (zh) | 2014-07-01 |
| JP6088063B2 (ja) | 2017-03-01 |
| JP2015537016A (ja) | 2015-12-24 |
| US9458105B2 (en) | 2016-10-04 |
| MX2015006162A (es) | 2015-08-14 |
| HK1212689A1 (zh) | 2016-06-17 |
| KR101713465B1 (ko) | 2017-03-07 |
| BR112015010693A2 (pt) | 2017-07-11 |
| EP2920162A1 (en) | 2015-09-23 |
| CN104812746A (zh) | 2015-07-29 |
| CA2890671A1 (en) | 2014-05-22 |
| CN104812746B (zh) | 2017-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015120216A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2015501833A5 (ru) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2015504067A5 (ru) | ||
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2013531031A5 (ru) | ||
| JP2014500295A5 (ru) | ||
| RU2018106453A (ru) | Соединения | |
| RU2016129953A (ru) | Фармацевтические комбинации | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2014518266A5 (ru) | ||
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| RU2012114846A (ru) | Соединение глицина | |
| RU2013154412A (ru) | Аминопиримидины в качестве ингибиторов syc | |
| RU2016141569A (ru) | Комбинации | |
| JP2011006480A5 (ru) | ||
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| RU2014135436A (ru) | Комбинация ингибитора rtk с антиэстрогеном и ее применение для лечения рака | |
| JP2014505107A5 (ru) | ||
| RU2015123499A (ru) | Соединения замещенной триазолбороновой кислоты | |
| RU2015121037A (ru) | Производные фенилэтилпиридина в качестве ингибиторов pde-4 | |
| RU2015141360A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2014530197A5 (ru) | ||
| RU2012135698A (ru) | Способ и композиция |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180129 |